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Survival Analysis of 314 Episodes of Sepsis in Medical Intensive Care Unit 
in University Hospital: Impact of Intensive Care Unit Performance and 
Antimicrobial Therapy
Aim To evaluate epidemiology of sepsis in medical intensive care unit (ICU) in a uni-
versity hospital, and the impact of ICU performance and appropriate empirical antibi-
otic therapy on survival of septic patients.
Methods Observational, partly prospective study conducted over 6 years assessed all 
patients meeting the criteria for sepsis at ICU admission at the Sisters of Mercy Uni-
versity Hospital. Clinical presentation of sepsis was defined according to 2001 Interna-
tional Sepsis Definitions Conference. Demographic data, admission category, source of 
infection, severity of sepsis, ICU or hospital stay and outcome, ICU performance, and 
appropriateness of empirical antibiotic therapy were analyzed.
Results The analysis included 314 of 5022 (6.3%) patients admitted to ICU during the 
study period. There were 176 (56.1%) ICU survivors. At the ICU admission, sepsis was 
present in 100 (31.8%), severe sepsis in 89 (28.6%), and septic shock in 125 (39.8%) pa-
tients with mortality rates 17%, 33.7%, 72.1%, respectively. During ICU treatment, 244 
(77.7%) patients developed at least one organ dysfunction syndrome. Of 138 (43.9%) 
patients who met the criteria for septic shock, 107 (75.4) were non-survivors (P<0.001). 
Factors associated with in-ICU mortality were acquisition of sepsis at another depart-
ment (odds ratio [OR] 0.06; 95% confidence interval [CI], 0.02-0.19), winter season (OR 
0.42; 0.20-0.89), limited mobility (OR 0.28; 0.14-0.59), ICU length of stay (OR 0.82; 
0.75-0.91), sepsis-related organ failure assessment (SOFA) score on day 1 (OR 0.80; 0.72-
0.89), history of global heart failure (OR 0.33; 0.16-0.67), chronic obstructive pulmonary 
disease (COPD)-connected respiratory failure (OR 0.50; 0.27-0.93), septic shock pres-
ent during ICU treatment (OR 0.03; 0.01-0.10), and negative blood culture at admis-
sion (OR 2.60; 0.81-6.23). Microbiological documentation of sepsis was obtained in 235 
(74.8%) patients. Urinary tract infections were present in 168 (53.5%) patients, followed 
by skin or soft tissue infections in 58 (18.5%) and lower respiratory tract infections in 44 
(14.0%) patients. Lower respiratory tract as focus of sepsis was connected with worse out-
come (P<0.001). Empirical antibiotic treatment was considered adequate in 107 (60.8%) 
survivors and 42 (30.4%) non-survivors. Patients treated with adequate empirical antibi-
otic therapy had significantly higher survival time in hospital (log-rank, P = 0.001).
Conclusion The mortality rate of sepsis was unacceptably high. The odds for poor out-
come increased with acquisition of sepsis at another department, winter season, limited 
mobility, higher SOFA score on day 1, history of chronic global heart failure, COPD-
connected respiratory failure, and septic shock present during ICU treatment, whereas 
longer ICU length of stay, positive blood culture, and adequate empirical antibiotic 
therapy were protective factors.
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Sepsis is a systemic response of the host to infec-
tious stimuli, which consists of clinical, hemo-
dynamic, biochemical, and inflammatory com-
ponents (1,2). When an organ system begins to 
fail because of sepsis, the condition is considered 
severe and is one of the leading causes of death 
in the critically ill, with the mortality rate of 28-
55% (3). The death rates in some subgroups of 
patients with sepsis-induced organ failure have 
decreased, even though there is no specific ther-
apy (2). The reduced mortality may be due to 
changes in the definition of sepsis, better detec-
tion and treatment of the underlying infection, 
or improved supportive care (4). Effective treat-
ment of organ failure is essential because the av-
erage risk of death increases by 15-20% with 
failure of each additional organ (5). The host re-
sponse is perhaps as important as the site of in-
fection or the type of microorganism causing 
sepsis. The lung is the most common site of in-
fection, followed by abdominal and urinary tract 
organs (6). Positive blood cultures are accept-
ed as the evidence of serious infection, but they 
are positive in only 30% of patients (6). Antimi-
crobial drugs are necessary, but not sufficient for 
the treatment of sepsis. Around 10% of the pa-
tients do not receive prompt antibiotic therapy 
for causative pathogen, and their mortality rate 
is 10-15% higher than in those who receive im-
mediate, appropriate antibiotic therapy (5). The 
adequacy of initial empirical antimicrobial treat-
ment is crucial in terms of outcome, although 
early mortality rate is unaffected by the appropri-
ate empirical antibiotic therapy (7). The applica-
tion of proven medical and technological inter-
ventions in a standard therapeutical algorithm is 
important in everyday performance of intensive 
care unit (ICU) (8). Since epidemiology and sur-
veillance data significantly differ between medi-
cal and surgical ICU patients (9), each ICU has 
to assess its own epidemiological data and estab-
lish critical pathways for the management and 
treatment of patients with sepsis (10).
Our aim was to evaluate the epidemiology of 
sepsis syndrome in the medical ICU at Universi-
ty Hospital and the impact of ICU performance 
and adequate empirical antibiotic therapy on the 
outcome in patients with sepsis.
Patients and methods
Patients
The study was conducted in an 11-bed medical 
ICU at Sisters of Mercy University Hospital, Za-
greb, Croatia. The patients with sepsis treated at 
the ICU between January 1, 2000 and Decem-
ber 31, 2002, were retrospectively included, and 
those admitted between January 1, 2003 and De-
cember 31, 2005, were included prospectively. 
Of 5022 medical ICU patients admitted during 
study period, 368 had an initial diagnosis of sep-
sis and 150 had a diagnosis of fever with suspect-
ed sepsis at ICU admission. All patients were 
referred to the ICU from the emergency depart-
ment. As the criteria for ICU admission were not 
standardized, the emergency department attend-
ing physician had to request the ICU admission 
on the basis of clinical condition of the patient. 
During the first 24 hours, 86 patients with inital 
diagnosis of sepsis and 118 patients with initial 
diagnosis of fever with suspected sepsis did not 
meet the criteria for sepsis (1,2) and thus were ex-
cluded from the study. The final sample consist-
ed of 314 patients who met the criteria for sepsis. 
Median age of the analyzed patients was 71 years 
(range, 19-92).
All patients with sepsis were treated by stan-
dard supportive treatment, fluid resuscitation, 
vasoactive drugs, medical and technological in-
terventions for organ dysfunction or failure (11), 
and empirical antibiotic therapy according to the 
hospital practice guidelines.
Method
Sepsis definition. Sepsis, severe sepsis, and sep-
tic shock were defined according to the crite-
ria of the American College of Chest Physicians 
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and the Society of Critical Care Medicine (1,2). 
Multiple organ dysfunction syndrome (MODS) 
was defined according to the criteria of Bulk 
(11). Patients in septic shock who met criteria 
for two or more organs failure before the start of 
ICU treatment were included in MODS group. 
Most patients had strong evidence of infection 
site, whereas patients with clinical criteria of sep-
sis but no evident source of infection were con-
sidered as having sepsis of unknown origin. Bac-
teremia was defined as positive blood culture to 
one or more microbial specimens. For common 
skin-dwelling bacteria, such as coagulase-nega-
tive staphylococci (SCN), two or more positive 
blood cultures were considered indicative. Noso-
comial infection was defined as the infection that 
developed 48 hours after admission to any hospi-
tal department or to other hospitals, but before 
ICU admission. New sepsis was defined as sepsis 
that developed 48 hours after ICU admission in 
a patient with chills or body temperature ≥38°C 
or ≤36°C and positive blood culture. Document-
ed sepsis was considered when a relevant micro-
organism was isolated from blood and suspected 
focus (pus, urine, sputum or quantitative trache-
al aspirate in intubated patients). If a catheter 
was considered as the source of infection, it was 
removed and culture was performed. Polymicro-
bial infection was considered when more than 
one organism was detected in the sample. Fungal 
infection was diagnosed when a fungus was iso-
lated in any sterile sample.
Empirical antibiotic therapy was considered 
adequate when at least one effective drug was in-
cluded in the treatment and the dose and pattern 
of administration were in accordance with med-
ical standards and in ICU survivors without mi-
crobiologically detected microorganism in blood-
stream or focus. When the empirical antibiotic 
therapy had to be changed after microbiological 
detection of microorganism, it was considered in-
adequate, whereas in non-survivors without mi-
crobiologically detected microorganism in blood-
stream or focus it was considered not evaluable.
Variables. The following variables were re-
corded: year of ICU treatment, patient age, sex, 
ICU and hospital length of stay, ICU and hos-
pital outcome, season of the year when the treat-
ment took place, type of infection (nosocomial 
or community acquired infection), suspected site 
of infection, patient mobility, emergency depart-
ment length of stay, time of the day of ICU ad-
mission, physician in charge on ICU admission 
and during the first hours of treatment, chron-
ic diseases (cardiovascular, pulmonary, cerebro-
vascular, liver, renal, malignancy, diabetes mel-
litus, and immunosuppression), clinical picture 
of sepsis (sepsis, severe sepsis, septic shock, or 
MODS) (1,2,11), development of organ dys-
function or failure and septic shock during treat-
ment, development of new sepsis and pseudo-
membranous colitis during treatment, need for 
mechanical ventilation, hemodialysis and sur-
gical intervention or percutaneous drainage as 
mandatory as part of the treatment of the infec-
tion, microbiologically documented infection in 
blood, urine and sputum/tracheal aspirate, mi-
croorganism isolated, and empirical antibiotic 
therapy. The severity of illness was evaluated by 
the Acute Physiology and Chronic Health Eval-
uation (APACHE II) score (12) on days 1 and 
3 and mental status by Glasgow Coma Score 
(GCS) (13,14) on days 1 and 3. Failure of or-
gans and severity of MODS (10) were evaluated 
by the Sepsis-related Organ Failure Assessment 
(SOFA) scale (15) on days 1 and 3. Organ dys-
function was defined by SOFA score 1 or 2, and 
organ failure by a SOFA score 3 or 4 (16).
Study design
Patients enrolled in the study were followed un-
til ICU or hospital death or hospital discharge. 
Five investigators assessed the patients for the 
eligibility for inclusion in the study according to 
the described criteria, and collected data through 
out the study period. All data were revised by two 
senior investigators (DV, SM), if any problem was 
detected patient history was evaluated. During the 
Croat Med J 2006;47:385-397
388
study period our unit did not participate in any 
trial designed to evaluate new therapies in sepsis.
Assays
All clinical and laboratory data were a part of 
the standard sepsis ICU management. Blood 
samples in standard ethylenediaminetetraacetic 
(EDTA)-K3 containing tubes were used for he-
matological assays on Coulter-Counter S plus ju-
nior (Coulter Electronics Limited, Luton, UK), 
coagulation parameters were assessed by Quick 
method from blood samples in 3.8% sodium ci-
trate tubes, 1:10 ratio, plasma was immediately 
separated by centrifugation (3000 G for 10 min-
utes) and analyzed automatically with Behring 
Coagulation Timer (Dade Behring, Marburg, 
Germany). Aspartat transaminase, alanin trans-
aminase, serum bilirubin, albumin, urea, cre-
atinine, and electrolytes were determined with 
commercially available kits on Olympus AU 600 
and Olympus Fractoscan junior (Olympus Di-
agnostica GmbH, Hamburg, Germany). Blood 
was cultured by the method of bedside inocula-
tion of blood culture bottles (FAN Aerobic and 
Anaerobic Culture Bottles, Organon Teknika 
Corp., Durham, the Netherlands). Microbiology 
analysis was preformed on a microbial detection 
system (Organon Bact-Alert, Organon Teknika 
Corp.).
Statistical analysis
Data were analyzed descriptively and results 
for continuous variables with normal distribu-
tion presented as means ±standard deviation 
(±SD) and those with non-normal distribution 
as medians with range. Homogeneity of vari-
ance was tested with Leven’s test. For those vari-
ables where variances were not homogenous, dif-
ferences between the groups were tested with 
Kruskal-Wallis test and compared with Mann-
Whitney test with post hoc Bonferroni correction 
(P<0.008). Qualitative variables were presented 
as frequency tables, and differences were tested 
with χ2 test by using Yates correction. The asso-
ciation between risk factors and death was first 
examined by means of univariate analysis. Mul-
tivariate analysis with logistic regression analy-
sis was used to evaluate the independent contri-
bution of the variables using a forward stepwise 
method. The odds ratio (OR) and the corre-
sponding 95% confidence intervals (CI) were 
calculated. Differences in survival were analyzed 
with the Kaplan-Meier method, data on surviv-
ing patients were censored at the date of hospi-
tal discharge, and data for non-surviving patients 
were censored at the date of hospital death, the 
results were compared with the use of log-rank 
test. P<0.05 was considered statistically signifi-
cant. Data analysis was performed with the Sta-
tistical Package for Social Sciences 10.0 for Win-
dows (SPSS Inc., Chicago, IL, USA).
Results
The number of septic patients in 2005 was sig-
nificantly higher in comparison with previous 
study years (χ2 test, P<0.001), when their num-
ber did not vary significantly (Table 1). There 
was no significant difference in the age of the 
patients among analyzed years (Kruskal-Wal-
Table 1. Proportion, age, and length of stay of patients with sepsis among all patients at the medical intensive care unit (ICU) in 2000-
2005 period
No. of patients Variable (median, range)
Year total with sepsis (%) age (years) ICU length of stay (days) overall  mortality rate (%)
2000  970  36 (3.7) 70.5 (22-92) 3 (1-22) 14.2
2001  928  36 (3.9) 70.5 (27-82) 5 (1-15) 13.1
2002  816  45 (5.5) 70 (19-92) 7 (1-36) 13.3
2003  734  56 (7.6) 70.5 (23-87) 6.5 (1-22) 17.9
2004  740  43 (5.8) 70 (31-87) 6 (1-35) 17.9
2005  834  98 (11.7) 72.5 (22-92) 6 (1-30) 20.3
Total 5022 314 (6.2) 71 (19-92) 6 (1-36) 17.4
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lis, P=0.911) or in ICU length of stay (Krus-
kal-Wallis, P=0.526). There were 176 (56.1%) 
ICU survivors and 138 (43.9%) ICU non-sur-
vivors. Fifteen patients (4.7%) died either in the 
step-down unit or during hospital stay. Finally, 
there were 161 (51.3%) hospital survivors and 
153 (48.7%) hospital non-survivors. During the 
first 24 hours of the ICU treatment, 35 deaths 
(11.1%) were recorded. Number of deaths in 
2002 (15 patients, or 33.3%) was significantly 
lower than in other years (P = 0.025). 
Of 55 patients (17.5%) who underwent car-
diopulmonary resuscitation during ICU treat-
ment, 53 (16.8%) did not survive. Nosocomi-
al origin of sepsis was found in 119 (37.8%) 
patients (Table 2). In-ICU mortality was associ-
ated with acquisition of sepsis at another depart-
ment (OR, 0.06; 95% CI, 0.02-0.19), winter sea-
son (OR, 0.42; 0.20-0.89), limited mobility (OR, 
0.28; 0.14-0.59), ICU length of stay (OR, 0.82; 
0.75-0.91), and SOFA score on day 1 (OR, 0.80; 
0.72-0.89).
There was no significant difference between 
survivors and non-survivors with respect to his-
tory of chronic diseases except for the presence 
of global heart failure (OR, 0.33; 0.16-0.67), and 
chronic obstructive pulmonary disease (COPD)-
connected respiratory failure (OR, 0.50; 0.27-
0.93; Table 3).
Hospital and ICU performance
More than half of the patients (51.6%) spent 
more than 3 hours in the emergency department 
and most were admitted to the ICU during the 
afternoon shift (Table 4). There was no differ-
ence in length of stay in emergency department 
between survivors and non-survivors. No differ-
ence in the outcome of patients admitted during 
the night shift was found (Table 4). Although 
more non-survivors were admitted to the ICU 
by a non-ICU physician (OR, 0.48; 95% CI, 
Table 2. Characteristics of patients with sepsis admitted to me-
dical intensive care unit (ICU) in 2000-2005 period and risk fac-
tors for in-ICU mortality








Age (years; median, range)  71 (19-92) 70 (22-90)  72.5 (19-92)
Sex:
 men 164 (52.2) 76 (46.3)  88 (53.6)
 women 150 (47.8) 85 (56.6)  65 (43.3)
Acquisition of sepsis:
 home 195 (62.1) 112 (63.6)  83 (60.2)
 nursing home  21 (6.7) 11 (6.3)  10 (7.2)
 another department†  74 (23.6) 39 (22.2)  35 (25.4)
 another hospital  24 (7.6) 14 (8.0)  10 (7.2)
Season:
 spring  68 (21.7) 45 (25.6)  23 (16.7)
 summer  67 (21.3) 38 (21.6)  29 (21.0)
 autumn  71 (22.6) 42 (23.9)  29 (21.0)
 winter‡ 108 (34.4) 51 (29.1)  57 (41.3)
Patient mobility:
 unlimited 114 (36.3) 86 (48.9)  28 (20.3)
 limited† 200 (63.7) 90 (51.1) 110 (79.7)
Length of stay 
(days, median, range):†
 ICU   6 (1-36)  7 (1-36)   3 (1-35)
 hospital  13 (1-107) 18 (3-107)   4 (1-77)
Scores (mean±SD):
 Day 1:
  GSC 10.84 ± 3.98 12.17 ± 3.40  9.15 ± 4.04
  APACHE II 19.98 ± 7.86 17.32 ± 7.24 23.37 ± 7.32
  SOFA†  5.82 ± 3.35  4.57 ± 3.09  7.42 ± 2.96
 Day 3:   (n = 243)   (n = 164)   (n = 79)
  APACHE II 15.72 ± 7.42 12.73 ± 5.88 21.91 ± 6.04
  SOFA  4.95 ± 3.47  3.77 ± 2.99  7.41 ± 3.11
*Abbreviations: ICU – intensive care unit; GCS – Glasgow Coma Score; APACHE 
II – Acute Physiology and Chronic Health Evaluation score; SOFA – sepsis-related 
organ failure assessment score.
†Stepwise logistic analysis, P<0.001.
‡Stepwise logistic analysis, P = 0.022.
Table 3. History of chronic disease in patients with sepsis and 
logistic regression analysis of risk factors for mortality in inten-
sive care unit








History of chronic heart failure:
 absent 205 (65.3) 130 (73.9)  75 (54.3)
 left-sided  11 (3.5)   5 (2.8)   6 (4.3)
 right-sided  51 (16.2)  27 (15.3)  24 (17.4)
 global*  47 (15.0)  14 (8.0)  33 (23.9)
History of chronic
respiratory disease:
 absent 245 (78.0) 151 (85.8)  94 (68.1)
 chronic obstructive pulmonary
  disease†
 59 (18.8)  22 (12.5)  37 (26.8)
 emphysema   3 (1.0)   1 (0.6)   2 (1.4)
  pleural fibrosis and calcification   7 (2.2)   2 (1.1)   5 (3.6)
Cerebrovascular disease:
 absent 212 (67.5) 122 (69.3)  90 (65.2)
 present 102 (32.5)  54 (30.7)  48 (34.8)
Malignancy:
 absent 266 (84.7) 154 (87.5) 112 (81.2)
 present  48 (15.3)  22 (12.5)  26 (18.8)
Chronic kidney disease:
 absent 222 (70.7) 131 (74.4)  91 (65.9)
 present  92 (29.3)  45 (25.6)  47 (34.1)
Diabetes mellitus:
 absent 174 (55.4)  94 (53.7)  80 (58.1)
 present 140 (44.6)  82 (46.3)  58 (41.9)
*Stepwise logistic analysis, P<0.001.
†Stepwise logistic analysis, P = 0.028.
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0.26-0.87), there was no significant association 
between survival and admission by ICU or non-
ICU staff. The severity of illness scores (GCS 
and APACHE II) and sepsis related organ dys-
function/failure score (SOFA) obtained on the 
arrival to the ICU showed that patients spent 
more than 3 hours in ED regardless of the pres-
ence of septic shock or impaired consciousness 
and/or organ dysfunction/failure syndrome 
(Table 5).
Clinical presentation
At the ICU admission, clinical picture of sep-
sis was present in 100 (31.8%) patients, severe 
sepsis in 89 (28.6%), and septic shock in 125 
(39.8%) patients. In the septic shock group, 39 
patients (12.4%) met criteria for two or more 
organs dysfunction/failure syndrome on the 
ICU admission (MODS group). Mortality rate 
for sepsis was 17.0%, severe sepsis 33.7%, sep-
tic shock 72.1% and MODS 74.4%. Until the 
ICU discharge or ICU death, 244 (77.7%) pa-
tients developed signs of at least one organ dys-
function (three organs, 68 (21.7%); two organs, 
52 (16.6%); four organs, 50 (15.9%); and a max-
imum of seven organs, 1 (0.3%) patient). The 
most frequent dysfunction was septic encepha-
lopathy, followed by hemodynamic instability, 
respiratory failure, renal failure, and disseminat-
ed intravascular coagulation (DIC). Thirteen pa-
tients with severe sepsis developed septic shock 
during the ICU treatment; at the end, out of 
138 (43.9%) patients who met criteria for septic 
shock at some point of the ICU treatment there 
were 107 (75.4) non-survivors (Table 6). Septic 
shock present during ICU treatment (OR, 0.03; 
0.01-0.10) and negative blood culture at admis-
sion (OR, 2.60; 0.81-6.23) were associated with 
a significant increase in risk of death. During the 
ICU treatment, 26 (8.3%) patients developed 
new sepsis, with no difference between survi-
vors and non-survivors (OR, 0.87; 0.16-4.77). 
Patients with sepsis, severe sepsis, septic shock, 
and MODS significantly differed in the severi-
ty of illness scores (GCS and APACHE II) and 
Table 4. Hospital and intensive care unit (ICU) performance and 
risk factors for in-ICU mortality








Time spent in emergency 
department (hours):
  ≤1  69 (22.0) 32 (18.2) 37 (26.8)
 >1, ≤2  46 (14.6) 25 (14.2) 21 (15.2)
 >2, ≤3  37 (11.8) 22 (12.5) 15 (10.9)
 >3 162 (51.6) 97 (55.1) 65 (47.1)
Time of ICU admission:
 08 am-04 pm 119 (37.9) 65 (36.9) 54 (39.1)
 04 pm-12 pm 153 (48.7) 84 (47.7) 69 (50.0)
 00 am-08 am  42 (13.4) 27 (15.3) 15 (10.9)
Physician in charge:
 ICU staff 152 (48.4) 92 (52.3) 60 (43.5)
 non-ICU staff 162 (51.6.) 84 (47.7) 78 (56.5)
*Stepwise logistic analysis showed no significant differences.
Table 5. Analysis of severity of Glasgow Coma Score (GCS), 
Acute Physiology and Chronic Health Evaluation score (APA-
CHE II), and sepsis-related organ failure assessment (SOFA) 
score on day 1 with respect to the length of stay in emergency 
department
Score Median (range) emergency department length of stay (h)
(day 1) ≤1 �n���� ( =69) >1, ≤�� �n����2 ( =46) >��, ≤�� �n�����3 ( =37) >3 (n=162) P*
GCS 13 (3-15) 10.5 (3-15) 12 (3-15) 12 (3-15) 0.167
APACHE II 20 (3-43) 19 (0-36) 19 (1-30) 21 (0-38) 0.122
SOFA  6 (0-13)  5.5 (0-15)  6 (0-11)  6 (0-13) 0.974
*Kruskal-Wallis test.
Table 6. Septic shock, new sepsis during treatment at intensive 
care unit (ICU), microbiological cultures in specimens obtained 
on admission, and risk factors for in-ICU mortality











 yes* 138 (43.9)  17 (19.3) 107 (75.4)
 no 176 (56.1) 142 (80.7)  34 (24.6)
Development of new sepsis
during ICU treatment:
 yes  26 (8.3)  17 (9.7)   9 (6.5)
 no 288 (91.7) 159 (90.3) 129 (93.5)
Blood culture on admission:
 none  24 (7.6)   4 (2.3)  20 (14.5)
 positive 154 (49.0) 107 (60.8)  47 (34.1)
 negative† 136 (43.3.) 65 (36.9)  71 (51.4)
Urine culture on admission:
 none  23 (7.3)   3 (1.7)  20 (13,9)
 positive 157 (50.0)  99 (56.3)  58 (42.3)
 negative 134 (42.7)  74 (42.0)  60 (43.8)
Smear/tracheal aspirate at admission:
 none 209 (66.6) 120 (68.0)  90 (65.2)
 positive  30 (9.6)  13 (7.4)  17 (12.3)
 negative  74 (23.6)  43 (24.6)  31 (22.5)
*Stepwise logistic analysis, P<0.001.
†Stepwise logistic analysis, P = 0.049.
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SOFA score recorded on day 1 (n = 314) and day 
3 (n = 243) (Table 7).
Of 314 septic patients, 61 (19.4%) need-
ed mechanical ventilation support that lasted 2 
days on average (range, 1-6), and 26 (8.3%) pa-
tients were on hemodialysis for 3 days on average 
(range, 1-22). Forty-one patients (13.1%) needed 
surgical intervention during sepsis treatment and 
only 13 (4.1%) developed MRSA pseudo-mem-
branous colitis as a complication of the treat-
ment.
Sepsis documentation
Microbiological documentation of sepsis was ob-
tained in 235 (74.8%) patients; bloodstream in-
fection alone was documented in 62 (19.8%) 
patients, urinary tract infection in 65 (20.7%) pa-
tients, and respiratory tract as the only source of 
infection in 16 (5.1%) as focus of sepsis. Eighty-
six (27.4%) patients presented with documented 
infection in bloodstream and focus, and 6 (1.9%) 
patients presented with documented sepsis of 
two different focuses. Positive blood culture rate 
obtained on admission was 49%.
The site of infection was determined by clin-
ical presentation and/or positive focus cultures. 
Urinary tract infections were the most com-
mon, followed by skin/soft tissue, lower respi-
ratory tract, and gallbladder/bile ducts infec-
tions (Table 8). Lower respiratory tract as focus 
of sepsis was associated with worse outcome (χ2 
test, P<0.001). Most patients had community 
acquired primary sepsis (Table 8). According to 
Table 7. Glasgow Coma Score (GCS), Acute Physiology and Chronic Health Evaluation score (APACHE II), and Sepsis-related Organ 









multiple organ dysfunction syndrome
(MODS) (n=39) multiple comparisons P†
Day 1:
 GCS   14 (3-15) 13 (3-15)  9 (3-15) 11 (3-15) sepsis/septic shock <0.001
sepsis/MODS <0.001
severe sepsis/septic shock  0.001
 APACHE II 15.5 (0-37) 20 (3-34) 24 (0-38) 26 (4-43) sepsis/severe sepsis  0.001
sepsis/septic shock <0.001
sepsis/MODS <0.001
severe sepsis/septic shock <0.001
severe sepsis/MODS  0.003
 SOFA   4 (0-13)  5 (0-12)  7 (0-15)  9 (1-14) sepsis/severe sepsis  0.001
sepsis/septic shock <0.001
sepsis/MODS <0.001
severe sepsis/septic shock <0.001
severe sepsis/MODS <0.001
septic shock/MODS  0.003
Day 3:     (n=90)    (n=75)    (n=51)    (n=27)
 APACHE II  11 (2-27) 15 (1-32) 21 (9-32) 18 (8-33)
 SOFA   2 (0-9)  4 (0-15)  7 (1-15)  9 (1-14) sepsis/MODS  0.002
*Kruskal-Wallis test, P<0.001 for all.
†post hoc Bonferroni correction for Mann-Whitney test (P<0.008).
Table 8. Site of infection and source of admission analysis in 
septic patients treated in medical intensive care unit (ICU) in 
2000-2005 period









 unknown   2 (0.6)   2 (1.1)   –
 upper respiratory tract   5 (1.6)   2 (1.1)   3 (2.2)
 lower respiratory tract  44 (14.0)  15 (8.5)  29 (21.0) 0.001
 urinary tract 168 (53.5) 100 (56.8)  68 (49.3) 0.186
 gallbladder and bile ducts  17 (5.4)  12 (6.8)   5 (3.6) 0.226
 gastro-intestinal tract  6 (1.9)   3 (1.7)   3 (2.2)
 wound/drainage  10 (3.2)   6 (3.4)   4 (2.9)
 foreign body   2 (0.6)   1 (0.6)   1 (0.7)
 central venous catheter   2 (0.6)   2 (1.1)   –
 skin/soft tissue  58 (18.5)  33 (18.8)  25 (18.1) 0.889
Source of admission:
 home 227 (72.3) 122 (69.3) 105 (76.1) 0.183
 department of medicine  31 (9.9)  18 (10.2)  13 (9.4)
 department of surgery  18 (5.7)  10 (5.7)   8 (5.8)
 department of urology   7 (2.2)   4 (2.3)   3 (2.2)
 department of gynecology   4 (1.3)   2 (1.1)   2 (1.4)
 department of dermatology   3 (1.0)   3 (1.7)   –
 department of rehabilitation   6 (1.9)   5 (2.8)   1 (0.7)
 other ICU   2 (0.6)   2 (1.1)   –
 other hospital  16 (5.1)  10 (5.7)   6 (4.3)
*χ2 test.
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the causative agent, Gram-negative sepsis was the 
most frequent, followed by Gram-positive and 
polymicrobial sepsis (Table 9). Escherichia coli 
was the most frequently isolated organism irre-
spective of the severity and clinical presentation 
of sepsis (Table 10).
Antimicrobial therapy
Empirical antimicrobial therapy was initiated in 
all patients chosen by the attending ICU physi-
cian following current Hospital recommenda-
tions. In 79 (25.1%) patients with no microbio-
logical documentation of sepsis, antimicrobial 
therapy was empirical until hospital discharge or 
death. The therapy was changed during the ICU 
stay in 34 of 79 (10.8%) patients on the basis 
of clinical judgment of ICU physicians. In 235 
(74.8%) patients with microbiologically docu-
mented sepsis the antibiotic treatment pattern 
was changed by attending ICU physician accord-
ing to the in vitro testing for antibiotic sensitiv-
ity, patient’s organ functions, and history of al-
lergy on antibiotics. We were able to evaluate the 
appropriateness of treatment in 266 patients (48 
non survivors with no microbiologically docu-
mented sepsis were considered not evaluable, and 
31 survivors with no microbiological documen-
tation of sepsis were considered as patients with 
adequate empirical antibiotic treatment). Em-
pirical antibiotic treatment was considered ad-
equate in 107 (60.8%) survivors and 42 (30.4%) 
non-survivors, and inadequate in 69 (39.2%) sur-
vivor and 96 (69.6%) non-survivors (Table 11). 
The survival of patients with adequate empirical 
antibiotic therapy compared to those with inad-
equate empirical antibiotic therapy or not evalu-
able treatment was significantly higher (Figure 1).
Discussion
The mortality rate of sepsis in most centers re-
mains unacceptably high (17). Similar to other 
life threatening conditions, the speed and appro-
priateness of therapy administered in the initial 
hours after the onset of disease influence out-
come (18). In the early 1990s, door-to-drug time 
of more than 60 minutes decreased to approx-
imately 30-35 minutes on average in patients 
Table 9. Microorganisms isolated in different site of infection and bloodstream in patients with sepsis obtained on admission to intensive 
care unit
No. (%) episodes of sepsis
Pathogen bloodstream infection (n = 154) urinary tract infection (n = 157) respiratory tract infection (n = 32) total (n = 343)
Gram-negative organisms:
 Escherichia coli  44 (28.6)  61 (38.8)  2 (6.3) 107 (31.2)
 Pseudomonas aeruginosa   4 (2.7)  26 (16.6)  3 (9.4)  33 (9.6)
 Proteus mirabilis   7 (4.5)  20 (12.7)  –  27 (7.9)
 Klebsiella pneumoniae   7 (4.5)  10 (6.3)  3 (9.4)  20 (5.8)
 Serratia marcenscens   3 (1.9)   3 (1.9)  1 (3.1)   7 (2.1)
 Acinetobacter species   2 (1.3)   4 (2.4)   6 (1.7)
 Salmonella enteritidis   4 (2.7)   –  –   4 (1.2)
  Hemophylus influenzae   –   –  1 (3.1)   1 (0.3)
 other enterobacteriaceae*   3 (1.9)  12 (7.7)  –  15 (4.4)
Gram positive organisms:†
 MSSA  19 (12.3)   3 (1.9)  2 (6.3)  24 (7.0)
 SCN  18 (11.7)   –  –  18 (5.3)
 MRSA   9 (5.8)   1 (0.6)  4 (12.5)  14 (4.1)
 Streptococcus pneumoniae  13 (8.4)   1 (0.6)  7 (21.9)  20 (5.8)
 Enterococcus   3 (1.9)   4 (2.4)  1 (3.1)   8 (2.3)
 Streptococcus pyogenes   4 (2.7)   –  1 (3.1)   5 (1.4)
 Streptococcus agalactiae   3 (1.9)   1 (0.6)  –   4 (1.2)
 Clostridium species   1 (0.6)   –  –   1 (0.3)
 Polymicrobial infection  10 (6.6)   5 (3.1)  2 (6.2)  17 (4.9)
Fungi:
 Candida species   –   7 (4.4)  5 (15.6)  12 (3.5)
Total 154 (100.0) 157 (100.0) 32 (100.0) 343 (100.0)
*Other enterobacteriaceae: Enterobacter species, Klebsiella oxytoca, Klebsiella species, Morganella morgani, Providencia rettgeri, and Providentia species.
†Abbreviations: MSSA – methicillin-sensitive Staphylococcus aureus; MRSA – methicillin-resistant Staphylococcus aureus; SCN – staphylococcus coagulase negative.
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with acute myocardial infarction (18). Critical 
pathways, such as door-to-drug time, are need-
ed as standardized protocols for optimizing and 
streamlining patient care, because many patients 
do not receive evidence-based therapies (9). Al-
though we implemented a critical pathway in 
managing patient with sepsis in emergency de-
partment in Sisters of Mercy University Hospi-
tal, an effort to reduce the time needed to per-
form all the various steps from the time a patient 
arrives in the emergency department to the time 
she or he arrives to the ICU, we did not record 
parallel improvement in the ICU mortality. The 
overriding goal of critical pathways is to optimize 
care by improving the use of appropriate treat-
ments and on facilitating patient triage to the ap-
propriate level of care, avoiding both under- and 
overutilization. Decreasing the use of inappro-
priate procedures can improve the quality of care 
while making that care more cost-efficient (10).
In the last 5 years, newly proven medical and 
technological interventions are being applied, 
such as recombinant human activated protein C 
(19), tight glucose control with insulin (20), ste-
roid administration to the patients with relative 
adrenal insufficiency and septic shock (21), and 
low tidal volume ventilation for acute respiratory 
distress syndrome (22). Adequate antibiotic use 
reduced mortality rate by 43.4% in patients with 
septic shock, by 23.1% in those with severe sep-
sis, and by 19.8% in those with sepsis (7), which 
are higher than those reported in studies using 
extremely expensive therapies (19,20).
Our study recorded constant increase in the 
number of patients with sepsis, particularly in 
Table 10. Most frequently isolated microorganisms in bloodstream documented infection in relation to clinical presentation of sepsis 
obtained on admission to intensive care unit
No. (%) episodes of sepsis (n = 314)
Pathogen sepsis (n = 100) severe sepsis (n = 89) septic shock (n = 86) multiple organ dysfunction syndrome (n = 39)
Documented bloodstream infection 48 (48.0) 43 (48.3) 41 (47.6) 22 (56.4)
Gram-negative organisms:
 Escherichia coli 12 (12.0) 12 (13.5) 13 (15.1)  7 (17.9)
 Pseudomonas aeruginosa  –  1 (1.1)  1 (1.1)  2 (5.1)
 Proteus mirabilis  4 (4.0)  –  3 (3.9)  –
 Klebsiella pneumoniae  3 (3.0)  2 (2.2)  –  2 (5.1)
 Serratia marcenscens  –  2 (2.2)  –  1 (2.6)
 Acinetobacter species  –  2 (2.2)  –  –
 Salmonella enteritidis  1 (1.0)  1 (1.1)  2 (2.3)  –
 Other enterobacteriaceae*  –  1 (1.1)  2 (2.3)  –
Gram positive organisms:†
 MSSA  9 (9.0)  5 (5.6)  3 (3.9)  2 (5.1)
 SCN  7 (7.0)  2 (2.2)  6 (7.0)  3 (7.7)
 MRSA  2 (2.0)  4 (4.4)  3 (3.5)  –
 Streptococcus pneumoniae  5 (5.0)  2 (2.2)  4 (4.7)  2 (5.1)
 Enterococcus  1 (1.0)  2 (2.2)  –  –
 Streptococcus pyogenes  2 (2.0)  1 (1.1)  1 (1.1)  1 (2.6)
 Streptococcus agalactiae  –  1 (1.1)  –  1 (2.6)
 Clostridium species  –  –  1 (1.1)  –
Polymicrobial infection  2 (2.0)  5 (5.6)  2 (2.3)  2 (5.1)
*Other enterobacteriaceae: Enterobacter species, Klebsiella oxytoca, Klebsiella species, Morganella morgani, Providencia rettgeri, Providentia species.
†Abbreviations: MSSA – methicillin sensitive Staphylococcus aureus; MRSA – methicillin resistant Staphylococcus aureus; SCN – staphylococcus coagulase negative.
Figure 1. Kaplan-Meier survival curve for hospital stay in patients with adequ-
ate (full line) and either inadequate or not evaluable empirical antibiotic therapy 
(dashed line). Log-rank, P = 0.001. Open circles and closed diamonds – number 
of deaths.
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2005, which was primarily attributable to hospi-
tal reorganization (closure of respiratory ICU), 
but also a result of the implementation of criti-
cal pathway for detecting and managing patients 
with sepsis with increased awareness and sensi-
tivity for the diagnosis, continuous educational 
efforts for ICU staff and non-ICU staff physi-
cians, better detection (microbiological and clin-
ical) and treatment of the underlying infection, 
and improved supportive care. The incidence of 
sepsis among medical ICU patients in our study 
was lower than that reported by French (23) 
and Spanish (7) authors in mixed type ICU. It 
was related to the increasing number of elderly 
and immunocompromised patients. Large pro-
portion of patients with sepsis in our study were 
men, those aged around 70 years, and those with 
reduced mobility, which is in accordance with 
other reports (7,23). Although the chances of de-
veloping sepsis differ for men and women by age, 
the likelihood of dying from sepsis is the same for 
men and women (24), which is consistent with 
our findings.
Survivors in our study had better severity 
of illness (GCS and APACHE II) and SOFA 
scores in comparison with non-survivors. How-
ever, we did not record any difference with re-
spect to emergency department length of stay, 
where over half of our patients spent more than 
3 hours. Time spent in emergency department 
was the same for patients with low and high 
probability of death, without adequate resusci-
tation therapy. On the other hand, there was no 
difference between management of patients and 
early mortality rate with respect to ICU or non-
ICU physician in charge. This fact proves that 
with firm ICU organization, implementation of 
critical pathways, and education of senior resi-
dents (non-ICU physicians) quality of care was 
on the same level (25) as even the vast majori-
ty of patients were admitted to the ICU during 
afternoon and night without difference in out-
come. A significant improvement in care of med-
ical ICU patients with sepsis is related to the im-
plementation of dedicated ICU staff specialist of 
intensive care medicine supervisors to residents 
and fellows. These observations are consistent 
with the results of other studies, which demon-
strated that changes in physician staffing pat-
terns favorably influenced the care of critically ill 
patients (26).
Analysis of the ICU outcome according to 
the clinical presentation of sepsis showed mortal-
ity rate for sepsis and severe sepsis similar to other 
studies (27,28). Factors that contributed to these 
outcome data remain speculative. This high mor-
tality found in our study is related to the high fre-
quency of severe systemic response present in the 
studied population. In the group of non-survi-
vors, there was a large proportion of patients ≥80 
years old with history of different chronic diseas-
es (chronic global heart and chronic obstructive 
pulmonary disease-connected respiratory failure 
were associated to worse outcome) who received 
Table 11. Mortality rate of patients in intensive care unit for va-
rious sites of infection depending on the adequacy of empirical 
antibiotic therapy









Urinary tract: 168 (53.5) 100 (56.8) 68 (49.3)
 adequate  85 (50.6)  60 (60.0) 25 (36.7)
 inadequate  61 (36.3)  40 (40.0) 21 (30.9)
 not evaluable  22 (13.1)   – 22 (32.4)
Skin/soft tissue:  58 (18.5)  33 (56.9) 25 (43.1)
 adequate  24 (41.3)  20 (60.6)  4 (16.0)
 inadequate  24 (41.3)  13 (39.4) 11 (44.0)
 not evaluable  10 (17.4)   – 10 (40.0)
Lower respiratory tract:  44 (14.0)  15 (34) 29 (66.0)
 adequate  19 (43.1)   8 (53.3) 11 (37.9)
 inadequate  14 (31.8)   7 (46.6)  7 (24.1)
 not evaluable  11 (25.1)   – 11 (38.0)
Gallbladder and bile ducts:  17 (5.4)  12 (70.5)  5 (29.5)
 adequate  10 (58.8)  10 (83.3)  –
 inadequate   6 (35.3)   2 (16.7)  4 (80.0)
 not evaluable   1 (5.9)   –  1 (20.0)
Upper respiratory tract:   5 (1.6)   2 (40.0)  3 (60.0)
 adequate   1 ((20.0)   1 (50.0)  –
 inadequate   4 (80.0)   1 (50.0)  3 (100.0)
 not evaluable   –   –  –
Others:*  20 (6.3)  12 (60.0)  8 (40.0)
 adequate   8 (40.0)   5 (41.6)  3 (37.5)
 inadequate   8 (40.0)   7 (58.4)  1 (12.5)
 not evaluable   4 (20.0)   –  4 (50)
Unknown:   2 (0.6)   2 (100.0)  –
 adequate   2 (100.0)   2 (100.0)  –
 inadequate   –   –  –
 not evaluable   –   –  –
*Others include wound/drainage (n=10), gastrointestinal tract (n=6), foreign body 
(n=2), and central venous catheter (n=2).
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limited proportion of treatment partly because of 
financial constraints. These constraints influence 
a variety of services including cost of first choice 
drugs, nursing, respiratory therapy (especially 
mechanical ventilation), radiology diagnostic 
procedures, possibility of surgical intervention, 
and available beds in ICU. These data are also 
associated to the disturbing increase of the cost 
of non-survivors length of the ICU stay and the 
level of care compared with that of survivors.
Previous studies estimates of the incidence 
of septic shock during sepsis treatment vary from 
23% to 50% (9). Our results showed that inci-
dence of organ dysfunction or failure syndrome 
during the time course of sepsis treatment was 
not connected only to the first hours of the treat-
ment. The reported incidence of organ failure 
varies according to the definition of failure and 
the patient population; however, when we used 
consensus definitions (1,2), a common pattern 
of frequency was observed. Lung dysfunction oc-
curs often and early and persists, whereas shock, 
which also occurs early, resolves rapidly or be-
comes fatal. Serious abnormalities of liver func-
tion, coagulation, and central nervous system 
function tend to occur hours to days after the 
onset of sepsis and persist for some time. In addi-
tion to the number of organ failures, the severity 
of each failure affects the prognosis (29). While 
sepsis may represent precursor state to develop-
ment of severe sepsis and septic shock with organ 
dysfunction or failure syndrome, patients should 
receive optimal treatment in ICU-s, and tech-
niques are needed for developing scores for pre-
dicting which patient will progress to clinical pre-
sentation of sepsis with poor outcome. Valles et 
al (30) found three variables that were indepen-
dently associated with an increase risk of death: 
APACHE II score at ICU admission ≥15, de-
velopment of septic shock, and adequacy of em-
pirical antibiotic treatment. Our data ruled out 
SOFA score on day 1, negative blood culture 
obtained at ICU admission, development of 
septic shock during ICU treatment, and inad-
equate empirical antibiotic therapy as variables 
associated with increase risk of mortality rate.
In or study, the main source of sepsis were 
urinary tract infections, followed by skin/soft 
tissue infections, lower respiratory tract infec-
tion and gallbladder/bile ducts infections. These 
four sources represented almost 91% of the ep-
isodes reported. Previously published studies 
(7,9,30,31) found that from the early 1990s, the 
most common source of sepsis were lower re-
spiratory tract infections, intraabdominal, and 
urinary tract infections ,compared with reports 
from the 1970s and 1980s when Gram-negative 
microorganisms from genitourinary tract and in-
traabdominal infections were the leading causes 
of sepsis. The results of the analysis of the micro-
biological characteristics of the sepsis in our study 
differ from those previously reported (7,9,26,30). 
In our study, Escherichia coli was the leading 
pathogen in infections with confirmed blood-
stream infection as well as focal infections. Other 
Gram-negative microorganisms are responsible 
for majority of sepsis documented in focus, while 
Gram-positive microorganisms are main patho-
gens in bloodstream infections. The incidence 
may be different from other countries where pa-
tients with higher degrees of severity of illness 
may be admitted to the ICU. Important obser-
vation is that 6.6% documented bloodstream in-
fections are polymicrobial. Sites of occult infec-
tion, rare or antibiotic resistant organisms, and 
polymicrobial infections make it impossible to 
ensure prompt, complete empirical coverage in 
all cases. A common approach is to initiate broad 
spectrum antibiotic treatment when the patho-
gen is uncertain and then narrow the therapy as 
microbiologic sensitivity data become available. 
Indiscriminate use of broad-spectrum antibiot-
ics has led to the development of resistant strains. 
While some studies have found that nosocomi-
al sepsis secondary to intra-abdominal focus of 
infection was associated with a higher mortali-
ty (9), which was consistent with our data, Val-
le et al (30) found that either origin of sepsis or 
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microorganism were not associated with poor 
prognosis in community acquired sepsis docu-
mented microbiologically in bloodstream. Wong 
et al (32) reported that in the group of patients 
with sepsis and APACHE II score ≥15 mortal-
ity rate of patients with urinary sepsis and septic 
shock was 11.5% compared with 36.2% when 
the septic shock was derived from other sources. 
The present study found that lower respiratory 
tract infection as focus of sepsis was associated to 
worse outcome.
Recently, Guarnacho et al (7) found that 
the risk of in-hospital mortality was eight times 
greater in medical patients receiving inappro-
priate antimicrobial therapy within the first 24 
hours and that choosing appropriate antibiotic 
did not influence early mortality rate. It depend-
ed rather on history of chronic diseases, severity 
of illness at admission, and development of or-
gan dysfunction or failure syndrome. Regarding 
the high mortality rate in cases without micro-
biologically documented sepsis, the worse out-
come of this episodes perhaps reflects an undiag-
nosed source of infection that might result in less 
aggressive approach and selection of appropriate 
empirical antibiotic.
The strengths of our study include the use of 
a national database that contained information 
over 6-year period, time interval appropriate for 
demographics, comorbidities, trends in pathogen 
microorganisms, and emerging new therapies. 
Our sample size was large enough to ensure that 
infrequent, but important, variables were not 
missed. Limitation of the study was that it was 
only partly prospective.
In conclusion, the clinical and demographic 
profile of patients with sepsis in our study shows 
that sepsis syndrome occurs most commonly 
among vulnerable patients, such as elderly and 
patients with multiple comorbidities. Our re-
sults confirmed that ICU management and per-
formance with fully trained specialists and resi-
dents in intensive care medicine who are able to 
perform early and aggressive resuscitation of pa-
tients with sepsis and promptly administer ap-
propriate empirical antimicrobial treatment is 
life saving. On the other hand, severity of illness 
of this group of patients was underestimated in 
the emergency department, which resulted in 
poor early resuscitation treatment and time de-
lay in ICU admission that might be fatal in such 
cases. Knowledge of the epidemiology of sepsis is 
increasingly important as new and extremely ex-
pensive treatment modalities become available 
for this condition. Rational plan for treating pa-
tients with sepsis is that each ICU should de-
velop critical pathways according to hospital re-
sources, both technological and human, estimate 
expected number of cases, the setting in which 
these cases are likely to occur, and the patients 
who are likely to benefit from optimal therapeu-
tical modalities.
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